Cardiac Science to renegotiate UK's HeartSine terms
This article was originally published in Clinica
Cardiac Science is terminating its agreement to buy a UK-based R&D company, HeartSine, which is developing cardiac arrhythmia detection algorithms and new defibrillation waveforms. Irvine, California-based Cardiac Sciences is attempting to gain better terms from the privately-owned HeartSine and is to "renegotiate under terms more favourable to Cardiac Science".
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.